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Abstract 5-Hydroxytryptamine type 2 antagonists are
used to treat symptomatic peripheral arterial disease. How-
ever, it remains unknown as to whether the administration of
sarpogrelate, a 5-hydroxytryptamine type 2 antagonist,
improves the prognosis after endovascular therapy for crit-
ical limb ischemia (CLI). We performed a retrospective
analysis using a database of 386 Japanese patients under-
going endovascular therapy for CLI. Sixty-seven patients
were treated with sarpogrelate, and we compared their
prognosis with that of an equal number of background-
matched controls extracted from the population. The
primary end point was the first event of either major
amputation or death from any cause, and amputation-free
survival was evaluated. The follow-up period was 21 ± 18
months (mean ± standard deviation), and 58 end points were
observed. Patients treated with sarpogrelate had a signifi-
cantly higher amputation-free survival rate than their
matched controls (P = 0.036). The hazard ratio for the end
point and its 95 % confidence interval was 0.57 (0.34–0.97).
These results suggest that sarpogrelate treatment is associ-
ated with a favorable prognostic outcome in CLI patients
undergoing endovascular therapy. Future prospective stud-
ies are required to investigate whether sarpogrelate treat-
ment would improve the prognosis of CLI patients.
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Introduction
Critical limb ischemia (CLI) is the most advanced stage of
peripheral arterial disease (PAD) characterized by chronic
ischemic rest pain or tissue loss [1], and is associated with
a poor prognosis for both life and limb and has a major
impact on the quality of life [2]. Even after revasculari-
zation, a substantial number of patients are still likely to
suffer a poor prognosis [3]. Therefore, it is of great interest
as to whether there is any medication that can modify their
prognosis after the revascularization procedures.
For the management of symptomatic PAD, clinical
guidelines recommend naftidrofuryl, a 5-hydroxytrypta-
mine type 2 (5-HT2) antagonist, as well as cilostazol, a
phosphodiesterase III inhibitor [1]. Previous clinical trials
revealed that both medications improve claudication in
PAD patients [4, 5]. Recently, some studies have reported
the promising effects of cilostazol on the prognosis of CLI
patients [6], whereas the effects of 5-HT2 antagonists still
remain to be investigated. Although naftidrofuryl is not
clinically approved in Japan, another 5-HT2 antagonist,
sarpogrelate, is available in clinical practice.
The aim of the current study was to investigate whether
the administration of sarpogrelate improves the prognosis of
Japanese patients undergoing endovascular therapy for CLI.
Patients and methods
We used a database of 411 consecutive CLI patients under-
going endovascular therapy in Kansai Rosai Hospital, Hyogo,
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Japan, between April 2003 and April 2010, which did not
include patients with thromboangiitis obliterans. The database
comprised patients’ clinical characteristics at baseline and
prospectively collected prognosis. Twenty-five patients (6 %)
were excluded because of missing data. We included the
remaining 386 patients (94 %), to retrospectively analyze the
association between the administration of sarpogrelate and
prognosis. The primary end point was the first event of either
major amputation or death from any cause, and amputation-
free survival was evaluated. Of the 386 patients, 67 (17 %)
were treated with sarpogrelate. Since the clinical backgrounds
were expected to be different between patients treated with
and without sarpogrelate, we compared the prognosis of the 67
patients treated with sarpogrelate with that of an equal number
of background-matched controls, extracted from the popula-
tion, without sarpogrelate treatment. The investigation was
approved by the ethics committee of Kansai Rosai Hospital,
and informed consent was obtained from all patients.
Data are given as means and standard deviations for
continuous variables or as percentages for dichotomous
variables. Differences of continuous variables between two
groups were evaluated by Student’s t test, whereas
dichotomous variables between two groups were compared
by the Fisher exact test, if not otherwise mentioned.
Amputation-free survival rate was plotted using the Kap-
lan–Meier method, and the difference between groups was
assessed by the log rank test. The Cox proportional hazards
regression model was used to calculate the hazard ratio of
sarpogrelate for the end point and its 95 % confidence
interval. The model was also used to assess the interaction
effect. A P value of less than 0.05 was considered statis-
tically significant. All statistical analyses were performed
using SPSS Statistics Version 19 (SPSS, Chicago, IL,
USA), except for pair matching, which was performed
using R version 2.13.0 (The R Foundation for Statistical
Computing).
Results
Of a total of 386 CLI patients, 67 (17 %) were treated with
sarpogrelate at baseline and the remaining 319 (83 %) were
not. Their clinical characteristics are shown in Table 1. The
patients treated with sarpogrelate had a lower prevalence of
diabetes mellitus (P = 0.034) and were less likely to be
treated with cilostazol (P = 0.004). None of the patients
were treated with prasugrel or had drug-eluting stents fitted
for revascularization. When the matched controls were
Table 1 Clinical characteristics
of CLI patients treated with or
without sarpogrelate
Data are mean ± standard
deviation or n (%)










Male 40 (60 %) 217 (68 %) 45 (67 %)
Age (years) 71 ± 14 71 ± 10 71 ± 11
Body mass index (kg/m2) 21.0 ± 3.2 21.4 ± 3.2 21.0 ± 2.7
Nonambulatory state 21 (31 %) 134 (42 %) 24 (36 %)
Fontaine stage IV 57 (85 %) 258 (81 %) 59 (88 %)
Infection 15 (22 %) 68 (21 %) 16 (24 %)
Revascularization procedures
Stent use 28 (42 %) 159 (50 %) 30 (45 %)
Self-expanding stent 27 (96 %) 136 (86 %) 29 (97 %)
Infrapopliteal revascularization 45 (67 %) 228 (71 %) 46 (69 %)
Comorbidities
Coronary artery disease 21 (31 %) 115 (36 %) 29 (43 %)
Cerebrovascular disease 20 (30 %) 105 (33 %) 17 (25 %)
Diabetes mellitus 41 (61 %) 239 (75 %)* 47 (70 %)
Hypertension 60 (90 %) 272 (85 %) 60 (90 %)
Dyslipidemia 49 (73 %) 246 (77 %) 53 (79 %)
Smoking 39 (58 %) 188 (59 %) 42 (63 %)
Hemodialysis 29 (43 %) 147 (46 %) 27 (40 %)
Antiplatelet therapy
Aspirin 55 (82 %) 282 (88 %) 56 (84 %)
Thienopyridines 17 (25 %) 113 (35 %) 18 (27 %)
Cilostazol 29 (43 %) 200 (63 %)* 33 (49 %)
More than one agent 36 (54 %) 220 (69 %)* 40 (60 %)
564 Heart Vessels (2014) 29:563–567
123
extracted and then compared with the 67 patients treated
with sarpogrelate, no significant differences in clinical
characteristics were observed between the two groups
(Table 1). The follow-up period was 21 ± 18 months, and
58 end points were observed. The period wherein revas-
cularization was performed was not significantly different
between the patients treated with and without sarpogrelate,
either before or after matching (P = 0.175 and 0.378, by
Mann–Whitney U test).
Figure 1 shows the amputation-free survival rate of
patients treated with sarpogrelate and their matched controls.
The patients treated with sarpogrelate had a significantly
higher rate of amputation-free survival than the matched
controls (P = 0.036 by log rank test). The hazard ratio for the
end point and its 95 % confidence interval was 0.57
(0.34–0.97). No interaction effect was observed between
sarpogrelate treatment and diabetes mellitus (P = 0.836).
Discussion
The current retrospective study suggests that the adminis-
tration of sarpogrelate is associated with a higher ampu-
tation-free survival rate in Japanese patients undergoing
endovascular therapy for CLI.
Management of cardiovascular ischemic diseases is a
challenging issue in clinical practice [7–15]. Management
of CLI is no exception; patients with CLI still have a poor
prognosis even after revascularization. It is of clinical
interest as to whether there is any treatment that can
improve their prognosis [16–18]. Sarpogrelate is a 5-HT2
antagonist and is now clinically approved for symptomatic
PAD in Japan. Although its mechanisms of action are not
yet fully understood, previous reports showed that sar-
pogrelate reduces platelet aggregation [19, 20], improves
endothelial function [21, 22], and enhances peripheral
circulation [23, 24]. In addition, some clinical trials have
demonstrated its favorable effects on cardiovascular dis-
eases [25] and skin ulcers [26], as well as intermittent
claudication [27]. On the other hand, the potential effects
of sarpogrelate on the prognosis of CLI remain unrevealed.
In the current study we performed a retrospective analysis
to investigate the association of sarpogrelate treatment with
the prognosis of CLI after endovascular procedures.
In the current study population, sarpogrelate was
administered to 17 % of the CLI patients undergoing
endovascular therapy. The patients with sarpogrelate treat-
ment were less likely to be treated with cilostazol
(P = 0.004), which would be clinically explainable. Both
sarpogrelate and cilostazol are expected to relieve PAD-
related symptoms, and clinicians would reasonably assume
the two medications as equals in the management of
symptomatic PAD [27]. Therefore, it would be no surprise if
patients already treated with one of the medications are not
treated with the other.
Another difference in clinical characteristics between
patients treated with and without sarpogrelate was the
prevalence of diabetes mellitus. Patients treated with
sarpogrelate had a lower prevalence of diabetes mellitus
(P = 0.034); in other words, diabetic patients were less
likely to be treated with sarpogrelate. Diabetic patients
often suffer decreased pain sensation [28, 29], so CLI
patients with diabetes mellitus might not feel foot pain as
severely as those without diabetes. Sarpogrelate is expected
to relieve the symptoms related to PAD. It would be no
surprise that the administration of sarpogrelate was asso-
ciated with the severity of symptoms. In the diabetic CLI
patients, less frequent complaints of pain might lead to less
frequent administration of sarpogrelate, although no data
were available about the severity of neuropathy and
symptoms in the current study population.
To minimize the prognostic influence of these different
clinical backgrounds, we used matched controls to perform
the comparison. As a result, the treatment with sarpogrelate
was significantly associated with a favorable prognostic
outcome (P = 0.036). However, the current analysis was
retrospectively performed, which is its major limitation. The
decision on the administration of sarpogrelate was left to the
judgment of each doctor. We could not obtain data about
the reason why each patient was treated with sarpogrelate.
Covariates that were not taken into consideration in the
current study might affect the prognostic findings. Whether
the administration of sarpogrelate can improve prognostic
outcome, therefore, still remains unrevealed. Nonetheless,
the current findings raise our clinical hope for prognostic
improvement by way of sarpogrelate treatment in CLI
Fig. 1 Amputation-free survival in CLI patients treated with and
without sarpogrelate. Amputation-free survival rates were estimated
by the Kaplan–Meier method. Patients treated with sarpogrelate (thick
line) had a higher amputation-free survival rate than the matched
controls (thin line) (P = 0.036 by log rank test). Error bars represent
standard errors
Heart Vessels (2014) 29:563–567 565
123
patients after endovascular therapy. Future prospective
controlled trials are required to confirm the efficacy of
sarpogrelate treatment for a favorable prognostic outcome.
In conclusion, sarpogrelate treatment was associated with
a favorable prognostic outcome in Japanese CLI patients
undergoing endovascular therapy. Future prospective stud-
ies are required to investigate whether sarpogrelate treat-
ment would improve the prognosis of CLI patients.
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